The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration’s policies on pricing and tariffs.
PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...
Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...
Pfizer released trial data on a new obesity drug, raising concerns about tolerability. Despite a stock drop, the company aims ...
Pfizer released trial data for its new obesity drug, raising questions about patient tolerability as company shares drop by over 3%. Despite potential side effects, Pfizer plans to advance numerous ...
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results